CA2900529A1 - Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma - Google Patents
Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma Download PDFInfo
- Publication number
- CA2900529A1 CA2900529A1 CA2900529A CA2900529A CA2900529A1 CA 2900529 A1 CA2900529 A1 CA 2900529A1 CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A CA2900529 A CA 2900529A CA 2900529 A1 CA2900529 A1 CA 2900529A1
- Authority
- CA
- Canada
- Prior art keywords
- fragment
- biological sample
- subject
- bcma
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762753P | 2013-02-08 | 2013-02-08 | |
| US61/762,753 | 2013-02-08 | ||
| PCT/US2014/015338 WO2014124280A1 (en) | 2013-02-08 | 2014-02-07 | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2900529A1 true CA2900529A1 (en) | 2014-08-14 |
Family
ID=51300158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2900529A Abandoned CA2900529A1 (en) | 2013-02-08 | 2014-02-07 | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10126301B2 (https=) |
| EP (1) | EP2954330A4 (https=) |
| JP (2) | JP2016507066A (https=) |
| CA (1) | CA2900529A1 (https=) |
| WO (1) | WO2014124280A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| WO2017072716A1 (en) * | 2015-10-30 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Prognostic method |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| WO2017201040A1 (en) | 2016-05-16 | 2017-11-23 | Berenson James Richard | Improved methods for monitoring immune status of a subject |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| EP3589952A4 (en) * | 2017-02-28 | 2021-03-10 | Menarini Silicon Biosystems S.p.A. | IMPROVED KITS AND TESTS FOR DETECTING CIRCULATING MULTIPLE MYELOMA CELLS FROM BLOOD |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| ES2644580B2 (es) * | 2017-07-26 | 2018-06-04 | Universitat Politècnica De València | Procedimiento de diagnóstico de lupus eritematoso sistémico (les) |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| MX2020004568A (es) | 2017-11-06 | 2020-10-05 | Juno Therapeutics Inc | Combinación de una terapia celular y un inhibidor de gamma secretasa. |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| CA3105448A1 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP7577647B2 (ja) * | 2018-08-31 | 2024-11-05 | エフ． ホフマン－ラ ロシュ アーゲー | Ｄｌｂｃｌについての予後指標におけるチミジンキナーゼ（ｔｋ－１） |
| GB2599228B (en) | 2019-02-21 | 2024-02-07 | Marengo Therapeutics Inc | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| CN119039441A (zh) | 2019-02-21 | 2024-11-29 | 马伦戈治疗公司 | 与nkp30结合的抗体分子及其用途 |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| AU2020416273A1 (en) | 2020-01-03 | 2022-07-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| WO2022216993A2 (en) | 2021-04-08 | 2022-10-13 | Marengo Therapeutics, Inc. | Multifuntional molecules binding to tcr and uses thereof |
| CN117305458B (zh) * | 2023-10-20 | 2024-06-21 | 四川省医学科学院·四川省人民医院 | TKTmRNA检测试剂在制备多发性骨髓瘤筛查试剂盒中的用途及试剂盒 |
| WO2026050572A2 (en) | 2024-08-29 | 2026-03-05 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| WO1998001151A1 (en) | 1996-07-10 | 1998-01-15 | Meiji Milk Products Co., Ltd. | Novel use of mk family as hematopoietic factor |
| GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US20040002068A1 (en) * | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| US7320991B2 (en) | 2001-02-27 | 2008-01-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health | Analogs of thalidomide as potential angiogenesis inhibitors |
| WO2003022877A1 (en) | 2001-09-06 | 2003-03-20 | Biogen Idec Ma Inc. | Crystal structure of baff, and use thereof in drug design |
| CA2523776A1 (en) | 2003-03-07 | 2004-09-23 | Xencor, Inc. | Baff mutants with at least one amino acid substitution and methods of their production |
| JP5570681B2 (ja) | 2004-08-31 | 2014-08-13 | 興和株式会社 | 抗ヒトｂａｆｆ抗体 |
| EP2332563A3 (en) | 2004-10-13 | 2013-03-13 | The Washington University | Use of BAFF to treat sepsis |
| US7947805B2 (en) | 2004-12-23 | 2011-05-24 | Merck Serono S.A. | BCMA polypeptides and uses thereof |
| EP1934258B1 (en) * | 2005-09-26 | 2011-03-02 | Enzo Life Sciences (ELS) AG | Antibodies against april as biomarkers for early prognosis of lymphoma patients |
| WO2007053732A2 (en) * | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| US8202698B2 (en) * | 2005-11-08 | 2012-06-19 | Biogen Idec Ma Inc. | Methods of evaluating BAFF |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| CA2644136A1 (en) | 2006-02-27 | 2007-09-07 | The Johns Hopkins University | Cancer treatment with gamma-secretase inhibitors |
| CA2651174A1 (en) | 2006-05-03 | 2007-11-15 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CA2720682A1 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| US9101559B2 (en) | 2009-05-08 | 2015-08-11 | New York University | Leukemic cell CNS infiltration controlled by notch-induced chemotaxis |
| US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
| KR101972446B1 (ko) * | 2011-05-27 | 2019-04-25 | 글락소 그룹 리미티드 | Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）결합 단백질 |
| WO2014068079A1 (en) | 2012-11-01 | 2014-05-08 | Max-Delbrück-Centrum für Molekulare Medizin | An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases |
| EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| CA2937320A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
| KR102526945B1 (ko) | 2014-04-30 | 2023-04-27 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Ｃｄ269에 대한 인간화 항체 |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| EP3154596A4 (en) | 2014-06-10 | 2018-01-24 | Institute for Myeloma & Bone Cancer Research | Anti-cancer effects of proteasome inhibitors in combination with glucocorticoids, arsenic containing compounds, and ascorbic acid |
| TW201618775A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| MY191537A (en) | 2014-12-05 | 2022-06-30 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| WO2016149350A1 (en) | 2015-03-17 | 2016-09-22 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing and treating cancer |
| WO2017019496A1 (en) | 2015-07-24 | 2017-02-02 | Berenson James Richard | Gamma secretase modulators for the treatment of immune system dysfunction |
| MX2018002043A (es) | 2015-08-17 | 2018-07-06 | Janssen Pharmaceutica Nv | ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS. |
| WO2017072716A1 (en) | 2015-10-30 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Prognostic method |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| WO2017201040A1 (en) | 2016-05-16 | 2017-11-23 | Berenson James Richard | Improved methods for monitoring immune status of a subject |
| BR112019002035A2 (pt) | 2016-08-01 | 2019-05-14 | Novartis Ag | tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2 |
| WO2018085363A2 (en) | 2016-11-02 | 2018-05-11 | Berenson James Richard | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| JP2020528885A (ja) | 2017-07-19 | 2020-10-01 | フェイト セラピューティクス，インコーポレイテッド | 養子免疫療法における免疫細胞調節のための組成物および方法 |
| US20220000872A1 (en) | 2018-10-31 | 2022-01-06 | Oncotracker, Inc. | Method of enhancing immune-based therapy |
-
2014
- 2014-02-07 WO PCT/US2014/015338 patent/WO2014124280A1/en not_active Ceased
- 2014-02-07 CA CA2900529A patent/CA2900529A1/en not_active Abandoned
- 2014-02-07 US US14/766,694 patent/US10126301B2/en active Active
- 2014-02-07 JP JP2015557128A patent/JP2016507066A/ja not_active Withdrawn
- 2014-02-07 EP EP14748765.6A patent/EP2954330A4/en not_active Withdrawn
-
2018
- 2018-05-09 JP JP2018090456A patent/JP2018136344A/ja active Pending
- 2018-09-28 US US16/146,300 patent/US12174189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014124280A1 (en) | 2014-08-14 |
| EP2954330A4 (en) | 2016-08-31 |
| US20160131654A1 (en) | 2016-05-12 |
| US12174189B2 (en) | 2024-12-24 |
| EP2954330A1 (en) | 2015-12-16 |
| JP2016507066A (ja) | 2016-03-07 |
| US10126301B2 (en) | 2018-11-13 |
| JP2018136344A (ja) | 2018-08-30 |
| US20190107541A1 (en) | 2019-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12174189B2 (en) | Diagnostic, prognostic, and monitoring methods for chronic lymphocytic leukemia | |
| EP3402515B1 (en) | Improved methods for monitoring immune status of a subject | |
| AU2014266223B2 (en) | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds | |
| US20180074074A1 (en) | Homogenous and heterogeneous assays and systems for determination of ocular biomarkers | |
| EP3458853B1 (en) | Improved methods for monitoring immune status of a subject | |
| EP3639028B1 (en) | Diagnostic, prognostic, and monitoring methods for breast cancer | |
| DK2551673T3 (en) | Methods for detecting cancer infiltration in the central nervous system | |
| CN106290812A (zh) | B细胞恶性肿瘤相关抗原表达量检测试剂盒及检测方法 | |
| WO2018085363A2 (en) | Cd147 detection in diagnostic, prognostic and monitoring methods for multiple myeloma | |
| CA3010019C (en) | Improved methods for monitoring immune status of a subject | |
| HK40082699A (en) | Improved methods for monitoring immune status of a subject | |
| CA3022481C (en) | Methods for monitoring immune status of a subject | |
| JP7577647B2 (ja) | Ｄｌｂｃｌについての予後指標におけるチミジンキナーゼ（ｔｋ－１） | |
| HK40000182B (en) | Improved methods for monitoring immune status of a subject | |
| HK40007456A (en) | Improved methods for monitoring immune status of a subject | |
| HK40007456B (en) | Improved methods for monitoring immune status of a subject | |
| WO2025195496A1 (en) | Immunotherapy for ox40 expressing cancer | |
| CN110612447A (zh) | 用于检测早期胰腺癌的测定 | |
| KR20150037321A (ko) | 방사선 피폭에 의한 간 손상 예측용 바이오마커 및 그 예측방법 | |
| WO2015151056A2 (en) | Mab-fcrn assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20200207 |